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The antibody display technology (ADT) such as phage display (PD) has 
substantially improved the production of monoclonal antibodies (mAbs) and Ab 
fragments through bypassing several limitations associated with the traditional 
approach of hybridoma technology. 
In the current study, we capitalized on the PD technology to produce high affinity 
single chain variable fragment (scFv) against Vascular Endothelial Growth Factor 
Receptor 2 (VEGFR2). VEGFR and its receptor (VEGFR2) play an important role in 
angiogenesis associated with tumor growth and metastasis. 
Methods and Results: 
To pursue production of scFv antibody fragments against human VEGFR2, we 
performed four rounds of biopanning using stepwise decreased amount of VEGFR2 
peptide (1 to 0.1 μg), a semi-synthetic phage antibody library (Tomlinson I + J) and 
TG1 cells. 
Antibody clones were isolated and selected through enzyme-linked immunosorbent 
assay (ELISA) screening. The selected scFv antibody fragments were further 
characterized by means of ELISA, PCR and Western blot analyses as well as 
fluorescence microscopy and Wound healing assay. Based upon binding affinity to 
VEGFR2, 5 clones were selected out of 30 positive clones enriched from PD in vitro 
selection. The selected scFvs displayed high specificity and binding affinity with Kd 
values at nm range to human VEGFR2. The immunofluorescence analysis revealed 
significant binding of the selected scFv antibody fragments to the HUVEC cell line. 
The effectiveness of the selected scFv fragments was further validated by Western 
blot analyses and Wound healing assay. 
Conclusions: 
Based on these findings, we propose the selected fully human anti- VEGFR2 scFv 
antibody fragments as potential immunotherapy agents that may be translated into 
preclinical/clinical applications. 
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